ArticleDrug delivery2025

Orchestrating T and NK cells for tumor immunotherapy via NKG2A-targeted delivery of a de novo designed IL-2Rβγ agonist.

Jie Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.